PRL 01
Alternative Names: PRL-01Latest Information Update: 28 Jul 2024
At a glance
- Originator Propella Therapeutics
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Herpes labialis
Highest Development Phases
- No development reported Herpes labialis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Herpes labialis in USA (Topical)
- 21 Dec 2023 Propella Therapeutics has been acquired by Astellas Pharma
- 16 Jun 2020 PRL 01 is available for licensing as of 16 Jun 2020. https://propellatx.com/about/investors-partners/ (Propella Therapeutics pipeline, June 2020)